Ontology highlight
ABSTRACT:
SUBMITTER: Simoens S
PROVIDER: S-EPMC5606961 | biostudies-other | 2017 Oct
REPOSITORIES: biostudies-other
Simoens Steven S Jacobs Ira I Popovian Robert R Isakov Leah L Shane Lesley G LG
PharmacoEconomics 20171001 10
Biosimilar drugs are highly similar to an originator (reference) biologic, with no clinically meaningful differences in terms of safety or efficacy. As biosimilars offer the potential for lower acquisition costs versus the originator biologic, evaluating the economic implications of the introduction of biosimilars is of interest. Budget impact analysis (BIA) is a commonly used methodology. This review of published BIAs of biosimilar fusion proteins and/or monoclonal antibodies identified 12 uniq ...[more]